Browse by Audience
Skip to content
Papers of the Week
Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature.
Abstract
Sintilimab is an immune checkpoint inhibitor (ICI). It can induce immune-related Adverse Events (irAEs). Severe adverse skin reactions are rare, but the mortality rate is high. We report the first case of successful treatment of adverse skin reactions using traditional Chinese medicine (TCM).